)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bliss GVS Pharma
Bliss GVS Pharma (506197) investor relations material
Bliss GVS Pharma Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary29 Oct, 2026
Executive summary
Q2 FY27 revenue reached 26,112.98 lakh standalone and 31,336.70 lakh consolidated; reported net profit was 7,356.54 lakh and 5,334.20 lakh, respectively.
H1 FY27 consolidated revenue was 59,894.26 lakh and net profit 10,471.40 lakh; standalone net profit included a 4,108.61 lakh impairment reversal.
Financial highlights
Standalone Q2 revenue was 26,112.98 lakh vs 19,022.53 lakh YoY; net profit was 7,356.54 lakh vs 3,861.77 lakh.
Consolidated Q2 revenue was 31,336.70 lakh vs 24,439.85 lakh YoY; net profit was 5,334.20 lakh vs 2,858.86 lakh.
Standalone H1 revenue was 48,271.49 lakh vs 35,358.96 lakh; net profit was 11,218.31 lakh vs 4,584.48 lakh.
Consolidated H1 revenue was 59,894.26 lakh vs 45,186.77 lakh; net profit was 10,471.40 lakh vs 7,294.99 lakh.
Q2 basic EPS was 6.93 standalone and 4.92 consolidated; H1 basic EPS was 10.58 and 9.65, respectively.
Segment performance
Operations comprise one operating segment: Pharmaceutical and Healthcare.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bliss GVS Pharma
- Revenue edged higher, but lower EBITDA and a ₹342 Mn disposal loss weighed on FY18 profit.506197
Q4 17/18 - Kenyan healthcare lifted consolidated growth as standalone pharma profit eased.506197Q4 16/17
- FY12 earnings rose sharply, with a substantial FX gain and export-led expansion plans.506197Q4 11/12
- Revenue surged, but cash flow weakened as expansion and export risks remained central.506197Q4 12/13
- FY11 sales and pretax profit rose, but PAT fell amid export concentration and expansion.506197Q4 10/11
- FY10 earnings rose as expansion plans advanced, alongside tax and internal-audit risks.506197Q4 09/10
- PAT advanced, but EBITDA and margins weakened as expansion investment accelerated.506197Q4 18/19
- Consolidated results weakened, while standalone growth and new capacity supported expansion plans.506197Q4 19/20
- Revenue rebounded, but a subsidiary impairment cut consolidated PAT to ₹231 Mn.506197Q4 21/22
Next Bliss GVS Pharma earnings date
Q3 26/279 Feb, 2027
Bliss GVS Pharma
Next Bliss GVS Pharma earnings date
Q3 26/279 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bliss GVS Pharma Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical formulations. The company offers dosage forms including suppositories, tablets, capsules, dry syrups, creams, and ointments across therapeutic segments such as anti-malarial, dermatology, gynecology, and anti-infectives. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.